Market Cap : 14.45 B | Enterprise Value : 14.58 B | P/E (TTM) : | P/B : 4.70 |
---|
NAS:BMRN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:BMRN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Biomarin Pharmaceutical's Long-Term Debt for the quarter that ended in Sep. 2019 was $844 Mil.
Biomarin Pharmaceutical's quarterly Long-Term Debt increased from Mar. 2019 ($835 Mil) to Jun. 2019 ($839 Mil) and increased from Jun. 2019 ($839 Mil) to Sep. 2019 ($844 Mil).
Biomarin Pharmaceutical's annual Long-Term Debt increased from Dec. 2016 ($661 Mil) to Dec. 2017 ($814 Mil) and increased from Dec. 2017 ($814 Mil) to Dec. 2018 ($830 Mil).
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.
From the Internet
- Zacks 2019-12-05 08:37:00
- Fool 2019-12-04 01:21:00